Hepatitis B correlation with acute or subacute-slow liver failure
Conditions
Interventions
1:The test group takes the treatment combined with traditional Chinese medicine based on Western medicine comprehensive treatment
2:Western medicine comprehensive treatment
Sponsors
The first Affiliated Hospital of Hunan University of TCM
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Inpatients who accorded with the diagnostic criteria of hepatitis B correlation with acute or subacute-slow liver failure; 2. Age between 18-65 years old; 3. Voluntary who have signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Acute liver failure,Subacute liver failure, Chronic liver failure; 2. Other causes including other virus infection, autoimmune, drugs, alcohol, toxic, metabolic disease such as Wilson disease lead to liver failure; 3. The chronic and acute (subacute), chronic liver failure caused by Hepatitis A virus (HAV), Hepatitis E virus (HEV), Hepatitis C virus (HCV) and Hepatitis D virus (HDV) superimposing with the chronic hepatitis B or hepatitis B liver cirrhosis; 4. The patients of hepatitis B-related liver failure can be associated with some late fatal complications, such as brain edema, serious infections (including septic shock, deep fungul infection, infection for more than two parts, superinfection), type I hepatorenal syndrome (clinical characteristics: serious, rapid and progressive renal failure, occurring oliguria in a few days or 2 weeks, serum creatinine >221 umol/L), the digestive tract hemorrhage, etc. 5. With primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and other autoimmune disease patients; 6. With extra hepatic obstructive jaundice leaded by stone or liver tumor; 7. Patients with combined fiber silting bravery hepatitis (FCH); 8. Pregnancy or lactation women; 9. With primary carcinoma of the liver or other tumors; 10. With other serious systemic disease or psychopath; 11. The patients who take immunosuppressive agent; 12. Anti-HIV -positive patients; 13. Drug addiction or alcohol addiction patients; 14. Patients who participated in other clinical subjects in recent three months; 15. Organ transplant patients; 16. Reluctant partners; 17. Other patients not in the exclusion standard, but researcher consider them not suitable for the research; 18. A person with any one possibility for the above will cannot take part in the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| the incidence of complications;Observe the TCM syndromes curative effect;Other liver function index (such as ALT, AST, ALB);MELD score change;The quality of life improved in follow-up period; | — |
Countries
China
Contacts
Public ContactKewei Sun
Outcome results
None listed